Examples of 'immunoconjugate' in a sentence
Meaning of "immunoconjugate"
Immunoconjugate refers to a combination of an antibody and another substance, such as a drug or toxin, that is used in targeted therapy for diseases like cancer
Show more definitions
- An antibody that has a second material as a conjugate
How to use "immunoconjugate" in a sentence
Basic
Advanced
immunoconjugate
The specific immunoconjugate is a cytocidal anthracycline derivative.
Immunoprecipitation of a melanoma cell extract with an immunoconjugate.
Synthesis of the mfVIIasm immunoconjugate in tumor cells.
The immunoconjugate compound has the formula.
The resulting heterodimeric protein is thus an immunoconjugate.
The immunoconjugate of the present description particlar comprises.
An antibody as disclosed herein can also be an immunoconjugate.
The immunoconjugate will be diluted in a suitable salt solution.
The antibody molecule may be in the form of an immunoconjugate.
The immunoconjugate of the present invention in particular comprises.
Schematic overview of the various immunoconjugate fusión formats.
Immunoconjugate technology is now generally known in the art.
Calicheamicin is another immunoconjugate of interest.
The immunoconjugate may further include an effector molecule.
The affinity reagent may be an antibody drug conjugate or immunoconjugate.
See also
An antibody or immunoconjugate of the invention is administered to the animal.
In one embodiment the engineered targeting antibody is comprised in an immunoconjugate.
An immunoconjugate is a conjugate of an antibody component with a therapeutic agent.
Downstream chromatography steps are utilized to further purify this immunoconjugate.
This immunoconjugate may bind to EpCAM expressed on cancer cells.
The same result was obtained with the mfVIIasm immunoconjugate.
Such an immunoconjugate may display a high variance in its efficacy.
An increasing hydrodynamic radius is an indication for aggregation of the immunoconjugate.
One type of immunoconjugate comprises an antibody component and a polypeptide cytotoxin.
Control plates contained no immunoconjugate.
The immunoconjugate may further comprise a pharmaceutically acceptable carrier medium.
The antibody portion of the immunoconjugate need not be immunoglobulin based.
An immunoconjugate according to the invention may be comprised in a pharmaceutical composition or medicament.
Clearance can be accelerated using an antibody that binds to the immunoconjugate.
Another immunoconjugate of interest comprises an antibody conjugated to one or more calicheamicin molecules.
This mixture of the radioisotope solution and the immunoconjugate can be incubated.
The immunoconjugate may comprise an antibody conjugated to one or more calicheamicin molecules.
Also described is a method comprising formulating the immunoconjugate into a pharmaceutical composition.
The immunoconjugate might comprise further molecules for example for stabilization.
Determining the extent of binding of the antibody or immunoconjugate compound to the cells.
The polypeptide or immunoconjugate of the invention is eluted with a linear or step salt gradient.
In another embodiment the radioimmunotherapy and immunotherapy or immunoconjugate therapy is repeated in several cycles.
Another immunoconjugate of interest comprises the glycoprotein conjugated to one or more calicheamicin molecules.
The pharmaceutical preparation comprising the immunoconjugate of the invention may be administered systemically.
The immunoconjugate can be formulated as a pharmaceutical composition comprising at least one acceptable excipient.
The method may further comprise detecting or imaging the immunoconjugate in the subject.
The ability of the antibody or immunoconjugate to inhibit or decrease tumor growth is measured.
An immunoconjugate including the antibody conjugated with a cytotoxic agent may be administered to the patient.
Generally this involves purifying the immunoconjugate and combining it with a physiologically acceptable carrier.
An immunoconjugate comprising the antibody conjugated with a cytotoxic agent can be administered to the patient.
Recombinant expression thus results in translation of the nucleic acid to yield the desired immunoconjugate.
In other examples the immunoconjugate comprises an antibody conjugated to one or more calicheamicin molecules.
The composition can be a pharmaceutical composition comprising a purified polypeptide or immunoconjugate and a pharmaceutically acceptable carrier.
The immunoconjugate may also be administered by aerosol to achieve localized delivery to the lungs.
These properties assist with targeting and tissue penetration of the immunoconjugate at the tumour site.
